Sitemap - 2023 - BowTiedBiotech
Epoch 52: 2023 in Review and Projections for 2024
Epoch 52: Sweat Equity: Your Weekly Biotech Fix
Epoch 52: Most Read Articles of 2023
Epoch 52: CRISPR Corner: Monthly Gene Editing Updates
Epoch 51: Biotech Success Formulas
Epoch 51: Sweat Equity: Your Weekly Biotech Fix
2024 Updates to BowtiedBiotech
Epoch 51: Innovation Recycling and Thematic Investing
Give the Gift of BowtiedBiotech
BowtiedBiotech Holiday Schedule
EPOCH 50 BIOTECH MARKET RESEARCH $IONS
Epoch 50: Biotech Business Models - Platforms vs Assets
Epoch 50: The Biopharma World is Waking Up
EPOCH 49: BIOTECH MARKET RESEARCH $EDIT
Epoch 49: Hot Topics in Genetic Medicine
🎁 CRISPR FRIDAY: 8 Quick Reads to Bring You Up to Speed $CRSP $VRTX
Epoch 49: Potential ChiMerica Reunion - a Catalyst for Biotech?
EPOCH 48: BIOTECH MARKET RESEARCH $GPCR $ALT $PFE
Epoch 48: Why Novel Antibiotic Development Does Not Attract Investment
Epoch 48: Biotech Trump vs Biden
EPOCH 47: BIOTECH MARKET RESEARCH $SWTX $PFE
Epoch 47: Obesity Update Ahead of Thanksgiving Feasts
EPOCH 46: BIOTECH MARKET RESEARCH ($ALDX)
Epoch 46: Everything You Need to Understand About Pharma Venture Capital in 2023
Epoch 46: The Biotech Bull vs Bear Seesaw
EPOCH 45: BIOTECH MARKET RESEARCH ($ICVX)
Epoch 45: Biotech Awards - Predictive or Not?
Epoch 45: Biotech Knocked Down, Not Out!
EPOCH 44: BIOTECH MARKET RESEARCH ($XENE)
Epoch 44: Biotech 2023-24 M&A Projections
Epoch 44: Tough Times for Most as Restructuring Spreads to Pharma
Invite your friends to read BowTiedBiotech
EPOCH 43: BIOTECH MARKET RESEARCH ($SRPT)
Epoch 43: Future Target Product Profiles for Delivering Mega-Blockbuster Products
Epoch 43: Private Biotech Capital Markets in Action
EPOCH 42: BIOTECH MARKET RESEARCH ($CRSP)
Epoch 42: Venture Capital Returns Not Worth the Time?
Epoch 42: Inside The Biotech Hive Mind
EPOCH 41: BIOTECH MARKET RESEARCH ($ACRS)
Epoch 41: Pfizer, Astrazeneca, and J&J Score at the Top of Recent R&D Rankings
Epoch 41: Q4 Biotech - Welcome to the Party!
EPOCH 40: BIOTECH MARKET RESEARCH ($ATRA)
Epoch 40: Emerging Therapeutic Modalities Expand the Universe of Druggable Targets
Epoch 40: Private Biotech In Focus
EPOCH 39: BIOTECH MARKET RESEARCH ($ARDX)
Epoch 39: PART 2 - R&D Budget Neutral Externalization Strategies
Epoch 39: Biotech Headwinds Swirl
EPOCH 38: BIOTECH MARKET RESEARCH ($FOLD)
Epoch 38: PART 1 - R&D Budget Neutral Externalization Strategies
Epoch 38: The Biotech Hype Index
EPOCH 37: BIOTECH MARKET RESEARCH ($AMAM)
Epoch 37: Three Key Industry Shaping Trends for Biopharma 2050
Epoch 37: Macro Hourglass Running Out of Sand
EPOCH 36: BIOTECH MARKET RESEARCH ($RVMD)
Epoch 36: Alternative Pharma Productivity Measures
Epoch 36: Post-Labor Day Biotech Off to a Slow Start
EPOCH 35: BIOTECH MARKET RESEARCH ($ALNY)
Epoch 35: IRA UPDATE - THE UNLUCKY 10
Epoch 35: Pharma Firepower For Fall M&A
SECTOR WATCH: Longevity Biotherapeutics
EPOCH 34: BIOTECH MARKET RESEARCH ($SLRN)
Epoch 34: The Biotech Rich Get Richer
Epoch 34: Biotech By Invite Only
EPOCH 33: BIOTECH MARKET RESEARCH ($BBIO)
Epoch 33: Global Biopharma - China and EU
Epoch 33: 1H23 Biotech Hedge Fund Performance
EPOCH 32: BIOTECH MARKET RESEARCH ($IMVT)
Epoch 32: Pharma Innovation Sourcing Trends
Epoch 32: RESTORE BIOTECH IN 2024
EPOCH 31: BIOTECH MARKET RESEARCH ($GRTX)
Epoch 31: Biopharma Herd Effect
EPOCH 30: BIOTECH MARKET RESEARCH ($SAGE)
Epoch 30: First-in-Class or Best-in-Class?
Epoch 30: 1H23 Biotech Trends - Alternative Views
EPOCH 29: BIOTECH MARKET RESEARCH ($CTXR)
Epoch 29: Predominant Biopharma Phenotypes in 2050
Epoch 29: Biotech Dog Days of Summer
EPOCH 28: BIOTECH MARKET RESEARCH ($FIXX)
Epoch 28: AI for Biopharma 2050
EPOCH 27: BIOTECH MARKET RESEARCH ($BBIO)
Epoch 27: Big Pharma vs. Big Tech
Epoch 27: Biotech Summer Kicks Off
EPOCH 26: BIOTECH MARKET RESEARCH ($BIIB)
Epoch 26: BIOPHARMA HISTORY & BEYOND (Part 3 of 3)
Epoch 26: The Biotech Beat Goes On
EPOCH 25: BIOTECH MARKET RESEARCH ($BMRN)
Epoch 25: BIOPHARMA HISTORY & BEYOND (Part 2 of 3)
Invite your friends to read BowTiedBiotech!
EPOCH 24: BIOTECH MARKET RESEARCH ($MLTX)
Epoch 24: BIOPHARMA HISTORY & BEYOND (Part 1 of 3)
Epoch 24: Regulatory & Macro Concerns Persist
EPOCH 23: BIOTECH MARKET RESEARCH ($QURE)
Epoch 23: HOW TO SUCCEED IN THE ABSENCE OF AN IPO MARKET
Epoch 23: EVERYTHING IS NOT WHAT IT SEEMS
EPOCH 22: BIOTECH MARKET RESEARCH ($BTAI)
Epoch 22: ASCO - Pfizer Overview ($PFE)
Epoch 22: ASCO - Merck Overview ($MRK)
Epoch 22: ASCO - AstraZeneca Overview ($AZN)
Epoch 22: ASCO - BMS Overview ($BMY)
Epoch 22: ASCO - Select Biotech Highlights
Epoch 22: ASCO - Novartis Overview ($NVM)
Epoch 22: ASCO - Roche Overview ($RHHBY)
Epoch 22: ASCO - J&J Overview ($JNJ)
Epoch 22: ASCO - AbbVie Overview ($ABBV)
Epoch 22: ASCO - Lilly Overview ($LLY)
Epoch 22: ASCO Week Commences - King Oncology Reigns Supreme in Biotech Land
EPOCH 21: BIOTECH PUBLIC MARKET RESEARCH ($RCUS)
Epoch 21: LIMITING THE DAMAGE OF THE INNOVATION REDUCTION ACT (IRA)
Epoch 21: Fundamentals to Drive Biotech > Macro…Maybe After the Debt Ceiling
🚨 EPOCH 20: BIOTECH MATERIAL EVENT
Epoch 20: Private Equity Deal Flow Forecasts Trouble for Biotech?
🚨 EPOCH 19: BIOTECH MATERIAL EVENT
Epoch 19: ANTIBODY DRUG CONJUGATES (ADCs)
Epoch 19: XBI Biotech Index Battles to Stay Above 80
🚨 EPOCH 18: BIOTECH MATERIAL EVENT
Epoch 18: TARGETED PROTEIN DEGRADATION
Epoch 18: Biotech Bounce as Banking Collapse Intensifies
🚨 EPOCH 17: BIOTECH MATERIAL EVENT
Epoch 17: Biotech Salary Survey
Epoch 17: Biotech Climbs the Wall of Worry
🚨 EPOCH 16: BIOTECH MATERIAL EVENT
Epoch 16: The SVB Event Impacts How Biotech CFOs Manage Cash Go-forward
Epoch 16: Biotech Investor Unmasking
🚨 EPOCH 15: BIOTECH MATERIAL EVENT
Epoch 15: Drug Prices are NOT Justified by R&D Spend
Epoch 15: Biotech Vacation Week
🚨 EPOCH 14: BIOTECH MATERIAL EVENT
Epoch 14: Analyzing Biotech Press Releases
Epoch 14: Biotech Treading Water
🚨 EPOCH 13: BIOTECH MATERIAL EVENT
Epoch 13: Man vs Machine - Automating Venture Capital
Epoch 12: Translating Innovation into Breakthrough Products
Epoch 12: BUY THE FCKING PIVOT(BTFP)
Epoch 11: Clinical Productivity Trends
Epoch 11 - Biotech Banking Blow-Up
🚨 BIOTECH MATERIAL EVENT (PAID CONTENT)
Epoch 10: Managing the SVB Bank Run Aftermath
Epoch 10 - Global Regulators Look to Rip the Heart From Biopharma Innovation
🚨 BIOTECH MATERIAL EVENT (PAID CONTENT)
Epoch 9: Pharma Business Model Dead on the Vine?
🚨 BIOTECH MATERIAL EVENT (PAID CONTENT)
Epoch 8: Biopharma Productivity Crashes
Epoch 8 - Biotech Macro Crabs Pull Down the Rest
🚨 BIOTECH MATERIAL EVENT (PAID CONTENT)
Epoch 7: Pharma Venture Capital Remains Steady
Epoch 7 - Is Biotech Hiring or Firing?
🚨 BIOTECH MATERIAL EVENT (PAID CONTENT)
Epoch 6: The Future of Medicine is NOT Being Rewarded by Wall Street
Epoch 6 - Biotech Blood in the Streets
🚨 BIOTECH MATERIAL EVENT ($LVTX)
Epoch 5: Is Pharma Too Big to Succeed?
Epoch 5 - Biotech Launch Countdown Initiated
🚨 BIOTECH MATERIAL EVENT(S): $LEGN
Epoch 4: Biotech Market Health - Down the Rabbit Hole
Epoch 4 - $XBI on a Crash Course to $90
🚨 BIOTECH MATERIAL EVENT(S): $AGEN, $PLRX
Epoch 3: Biotech’s Own Cellicon Valley - Philadelphia
Epoch 3 - JPM Hangover Week for Biotech
🚨 BIOTECH MATERIAL EVENT(S): $ZYME $BCEL $VKTX
Epoch 2: Sailing Through the Biotech Storm, Shorelines Spotted?
🚨 BIOTECH MATERIAL EVENT: $SGEN
Epoch 2: Party Like It’s 2020 - JPM Week is BACK!
Epoch 1 - The Biotech "Buzz" Index (Winners & Losers)